On February 10, 2026, Isomorphic Labs — a spinoff of Google DeepMind founded by Nobel Prize winner Demis Hassabis — released a technical report that stunned the drug discovery world. The company unveiled IsoDDE, an AI system that outperforms every existing tool for predicting how potential drugs bind to proteins in the human body.

The numbers are striking. IsoDDE is two times better than AlphaFold 3 — the Nobel Prize-winning AI system — on the hardest protein-ligand binding predictions. It is 20 times better than competing models on antibody predictions. And it can predict binding affinities — a critical measure of drug effectiveness — more accurately than physics-based methods that take days to run.

This is an AMAZING moment because it represents the collision of two transformative technologies: artificial intelligence and biology. For decades, drug discovery has been slow, expensive, and failure-prone. The average new drug takes 10 to 15 years to move from concept to market and costs approximately $2.6 billion. Most candidates fail. The process is fundamentally a search problem — finding the right molecule out of trillions of possibilities that will bind to a disease target without causing harmful side effects.
IsoDDE changes the economics of that search. Instead of testing thousands of compounds in expensive lab experiments, researchers can now predict which molecules are most likely to work before ever synthesizing them. The AI does not just predict structure — it predicts binding affinity, interaction dynamics, and pocket discovery all in one unified system. It is the first tool that can handle the full drug design pipeline computationally.

Why does this matter to you? Because the drugs that could save your life or the life of someone you love are sitting undiscovered in a space of molecular possibilities so vast that traditional methods cannot search it in any reasonable timeframe. Rare diseases go untreated because the patient population is too small to justify the cost of drug development. Antibiotic resistance is rising faster than new antibiotics are being developed. Cancer treatments that work for some patients fail for others because we cannot predict which molecules will target their specific mutations.

IsoDDE does not solve all of these problems. But it makes them tractable in a way they were not before. Mohammed AlQuraishi, a computational biologist at Columbia University, called it “a major advance, on the scale of an AlphaFold 4.” The system can predict drug-protein interactions for molecules that are vastly different from the data it was trained on — the hardest problem in computational drug design. That suggests the AI has learned something fundamental about molecular interactions, not just memorized patterns.

And this is not theoretical. Isomorphic Labs has already integrated IsoDDE into partnerships with pharmaceutical giants Eli Lilly and Novartis. The system is being used right now to design real drugs for real diseases. The first medicines discovered with this technology could enter clinical trials within the next two years. If they succeed, they will prove that AI-designed drugs can move from concept to patient faster than anything developed through traditional methods.

I am Henry P., and I believe this is a turning point for medicine. The transition from lab-based drug discovery to AI-accelerated design is happening faster than most people realize. IsoDDE is not a research project. It is a production system already deployed in the pharmaceutical industry. The speed at which this technology has moved from academic breakthrough to commercial application is unprecedented.

But I want to be honest with you about what this does and does not mean. AI can accelerate the discovery phase of drug development. It cannot eliminate the need for clinical trials. Even the most perfectly designed molecule still has to be tested in humans to prove it is safe and effective. That process takes years and is governed by regulatory frameworks designed to protect patients. IsoDDE does not bypass those safeguards. It makes the front end of the pipeline faster, not the back end.
And there is a philosophical complexity here worth acknowledging. Isomorphic Labs has chosen to keep IsoDDE proprietary. Unlike AlphaFold, which was released openly and has been used by millions of researchers worldwide, this system is available only to paying partners. That decision has sparked debate in the scientific community. Open-source advocates argue that the most important breakthroughs in AI should be accessible to everyone. Isomorphic argues that building and maintaining a system of this sophistication requires resources that only a commercial model can sustain.
Both perspectives have merit. What is inarguable is this: the era of AI-designed drugs is here. The first generation of medicines discovered primarily by algorithms, not chemists, will reach patients in the next few years. And the question is no longer whether AI can revolutionize drug discovery. It is how fast that revolution will unfold.

Sources:
∙ Nature, “‘An AlphaFold 4’ – scientists marvel at DeepMind drug spin-off’s exclusive new AI,” February 19, 2026.
https://www.nature.com/articles/d41586-026-00365-7
∙ LabCritics, “Isomorphic Labs’ Drug Design Engine Promises to Outdo AlphaFold 3,” February 18, 2026.
https://labcritics.com/isomorphic-labs-drug-design-engine-promises-to-outdo-alphafold-3/
∙ Tech Startups, “AI Accelerates Drug Discovery from Decades to Months: Isomorphic Labs’ Drug Design Engine Pushes Beyond Nobel-Level Science,” February 10, 2026.
https://techstartups.com/2026/02/10/ai-accelerates-drug-discovery-from-decades-to-months-isomorphic-labs-drug-design-engine-pushes-beyond-nobel-level-science/